Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • ICMR partners with...

    ICMR partners with IVI, invests Rs 3.20 crore for vaccine development in India

    Written by Ruby Khatun Khatun Published On 2017-08-22T11:30:27+05:30  |  Updated On 22 Aug 2017 11:30 AM IST
    ICMR partners with IVI, invests Rs 3.20 crore for vaccine development in India

    New Delhi: The Indian Council of Medical Research (ICMR) and the Union Ministry of Health inked a pact with the International Vaccine Institute (IVI), South Korea to collaborate on vaccine research and development.


    The Memorandum of Understanding (MoU) was signed between Dr Soumya Swaminathan, Director General of ICMR and Secretary, Department of Health Research, Manoj Jhalani, Additional Secretary, Ministry of Health and Dr Jerome H Kim, Director General of IVI.


    The ICMR in Delhi is the apex body in the country for the formulation, coordination and promotion of biomedical research.


    With a long history of scientific collaboration with IVI, India officially became a signatory to the treaty of the Seoul-based organisation in 2012. The IVI has 35 signatory countries.


    With this partnership, India is committing an annual contribution of USD 5,00,000 (Rs 3.20 crore) to IVI and joins Sweden and South Korea as financially contributing signatories to IVI, an official statement said.


    The IVI has been partnering with Indian vaccine manufacturers, research institutes, government and public health agencies on vaccine development, research and training.


    One of the most successful collaborations was with Shantha Biotech on the development of Shanchol, the world's first low-cost oral cholera vaccine. The vaccine was licensed in India in 2009 and WHO-prequalified in 2011.


    The IVI successfully collaborated with health authorities in Odisha to introduce the oral cholera vaccine for the first time in India in 2011, the statement said.


    In addition, IVI has collaborated with the National Institute of Cholera and Enteric Diseases (NICED), Kolkata on research and training projects, including the establishment of a vaccine evaluation lab at NICED.


    "India is a vaccine industry powerhouse that supplies 60 per cent of the world's vaccines for vaccine-preventable diseases and 60-80 per cent of annual UN vaccine purchases (2012)," Dr Kim, Director General of IVI, said.


    "The signing of the MoU is a continuation of our partnership with India to provide safe, effective and affordable vaccines for people around the world. We look forward to having India's representation on the IVI Board of Trustees which will increase engagement with Indian academia and industry even further," the DG said.


    ICMR's Dr. Swaminathan said, "We have been working closely with IVI in India for more than a decade now. We are confident that this collaboration will elevate the vaccine research and development capacity at IVI as well as Indian labs and further benefit India's vaccine industry."


    Jhalani said the partnership will help better address vaccine needs of children in the country and ultimately contribute to protecting people from infectious diseases.

    Dr Jerome H KimDr Soumya SwaminathanICMRIndiaIndian Council of Medical ResearchInternational Vaccine InstituteIVIManoj JhalaniMemorandum of UnderstandingMinistry of HealthMoUNational Institute of Cholera and Enteric Diseasespartnershipsign pactSouth KoreaUnion Ministry of Health and Family Welfarevaccine
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok